biotech stocks

Is This a Biotech Bubble?

biotech bubble

Wall Street pundits are claiming we are on the precipice of a biotech bubble because biotechnology stocks have been soaring. The Nasdaq Biotechnology Index has climbed 44% in the last year. The Nasdaq Composite and S&P 500 have climbed just 9% and 11% in the same time.

But it's the last week that has traders panicked about "bubble" territory.

From March 20 through March 26, the Nasdaq biotech index dipped 7%. The S&P biotech index dropped almost 11%.

These tremors could signify a correction in the coming months - but make no mistake - the "bubble" is not about to burst on biotech stocks...

Biotech ETF Performance Shows Rally Is Not A Fluke

biotech etf

For weeks now biotech stocks have headlined our list of top stocks to invest in for 2015.

And a particular biotech ETF is showing signals that this is rally is sector-wide, not confined to the smaller companies who get big lifts from specific price catalysts.

Here's why biotech stocks are so hot in 2015, and what this biotech ETF is telling us...

This $6 Biotech Stock Is Opening the Door to True "Personalized Medicine"

Stealth Profits Trader – update from D.R. Check your email or moneymappress.com. Reply STOP to opt out of texts

We've found a great biotech stock that's riding a super powerful trend. The company develops and markets diagnostic technologies.

And its technology is likely to stir the $50 billion in vitro diagnostics (IVD) industry. Plus, an "outsider" investor just recently bought up 15% of the company's shares.

Here's why we're loving this biotech stock...

Top Pharmaceutical Companies Continue Massive M&A – Here's Your Profit Play

Top pharmaceutical companies

Two of the world's top pharmaceutical companies have announced a merger today (Thursday), and that's another major buy signal for one of our favorite profit opportunities.

AbbVie Inc. (NYSE: ABBV) officials announced they will purchase Pharmacyclics Inc. (Nasdaq: PCYC) for roughly $21 billion.

 

The deal gives Abbvie access to one of the world's top-selling cancer drugs, Imbruvica. Revenue from Imbruvica alone is expected to hit $1 billion in 2015 and $5.8 billion by 2020.

3 of the Best Biotech Stocks to Buy Today

best biotech stocks

If you're looking for the best biotech stocks on the market, you've come to the right place.

Our biotech specialists aren't considered to be among the best... they are the best.

And they picked three of the best biotech stocks to profit from today...

Another of Our Top Stocks to Invest in Is Up 50% in 2015

Biotech stocks have been hot this year. Two of our top stocks to invest in are up more than 50% on the year.

Last week we talked about Novavax Inc. (Nasdaq: NVAX). While still on a roll this year, we cautioned investors. It's a biotech company still in its clinical-stage and could be overheating.

Here's another biotech that's hot, but still has room to keep going...

The Seven Financial Indicators of Highly Successful Biotech Investors

Tech molecule

When evaluating biotech stocks, many key indicators that work for other industries - e.g. price-to-earnings ratio, profit margin, revenue-per-share - often don't apply.

Here's why they don't, and why seven of these critical financial indicators do...

60 Biotech Companies to Go Public Before April 1

biotech companies

Biotechnology is tech's fastest-growing sector. In fact, there are more than 100 biotech companies set to go public in 2015.

Of those 100 IPOs, 60 are expected to launch before April 1. So you have to move fast to ride this $320 billion biotech wave.

Those IPOs are all but certain to keep the biotech bull market going through the year. Biotech stocks have soared 290% in the past five years. That's more than triple the S&P's 88%.

And biotech IPOs are not the only catalysts that will lift biotech shares across the board in 2015.

2015 Stock Picks: Biotech Surges Alongside Precious Metals

2015 stock picks

Our 2015 stock picks show us two trends.

Precious metals are still surging. And now, biotech stocks are coming into 2015 hot.

Take a look at these exciting developments for our top stocks in 2015...

This Blockbuster Drug Has Room to Run

biotech stocks

Editor's Note: We're sharing this Private Briefing with you because it contains a pick that's put Bill's readers up as much as 444% since he first recommended the stock...

Shares of blood-cancer drugmaker Pharmacyclics Inc. rocketed as much as 22% last Tuesday after the company exhilarated investors by forecasting that sales of its key drug would double this year.

We weren't surprised by this, of course.

But even more important was that Private Briefing readers weren't, either.

In a Private Briefing report back in early December, we said the Pharmacyclics blood-cancer drug Imbruvica (ibrutinib) was well on its way to becoming the blockbuster we predicted when we first recommended shares of the Sunnyvale, Calif.-based biotech back in April 2012.

That "call" was right on target.

Late last Monday, after the close of trading, Pharmacyclics said net-product revenue for Imbruvica for full-year 2014 would come in at $492 million. That would include sales of about $185 million in the fourth quarter alone - a hefty "sequential" (quarter-to-quarter) jump of 31%.

But here's the real stunner: For 2015, the company is looking at sales to more than double and reach $1 billion.

For those who want the actual numbers, that's a gain of 103%.

Imbruvica, you see, is shaping up to be the very blockbuster we told you it would be.
And that bodes well for Pharmacyclics shares.

Let's take a look...

5 Pharmaceutical Stocks to Avoid

pharmaceutical stocks

Pharmaceutical stocks can plummet for myriad reasons: loss of funding, lawsuits, poor clinical trials.

It's a risky sector to get yourself involved in - one with big rewards. But, where there are big rewards, there are also big losses.

We took a look at five pharmaceutical stocks you should avoid...

The Best Biotech Stocks to Buy in 2015

biotech stocks to buy in 2015

Biotech stocks to buy in 2015: Biotech was one of the most profitable sectors this year. Through Dec. 18, the S&P 500 Biotechnology Index is up 43.6% in 2014, and the Nasdaq Biotechnology Index is up 36.9%.

Those gains are three to six times as big as the broader markets'. In 2014 through Dec. 18, the Dow Jones Industrial Average is up just 6.1%, the S&P 500 10.3%, and the Nasdaq 12.8%.

With those profits in mind, we've picked the three best biotech stocks to buy in 2015, plus one bonus investment. Take a look...

These Biotech Stocks to Buy Profit from Today's "Miracle Cures"

biotech stocks to buy

When researching the best biotech stocks to buy, investors often look for companies that will cure terrible, chronic diseases.

Until recently, these biotech stocks have been elusive. But now that's changing - thanks to an industry known as personalized medicine.

In his 20 years' experience, Tremblay has covered every type of biotech stock and company on the market. And when he talks about the personalized medicine field, he describes the treatments as "miraculous." Here's why...

This Biotech Stock Winner Has Wall Street Fooled

biotech stock

Today I want to reintroduce you to a biotech stock that Wall Street has been pricing as though it were dead money.

This biotech company recently filed a stellar earnings report. But those earnings were slightly off analyst expectations, and the share price dipped.

But Wall Street's ignorance gives us an entry point the likes of which we probably won't see again for years...

One Stock That Will Profit from a New, Breakthrough Medical Direction

Medical doctor male

Modern medicine, for all of its sophisticated drugs, complex gadgets, and amazing surgical procedures, rarely cures anything. It treats. It manages. It postpones the inevitable.

But return a patient to normal, optimal health?

Seldom...

So when an innovation comes along that can effect a complete and permanent remission of disease or restore damaged organs to a pristine state, it should cause your keenest investing instincts to perk up and pay attention...

© 2015 Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201, Email: customerservice@MoneyMorning.com